Sanofi Consumer Healthcare Q2 FY26: Revenue up 7%, PBT up 16% YoY

Auditor Mid Year ChangeEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

SANOFICONR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹4700.30

prior close

₹4914.90

announcement price

After-mkt

timing

Nifty Microcap 250market+0.5%-0.1% vs market

Pharmaceuticals peers, median of 160sector+0.8%-0.4% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.2

10m

-3.1

15m

-3.3

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+0.5-0.1+0.8-0.4

Next day

-2.1-0.1-2.0+0.0-2.1

-2.1+1.0-3.0+0.1-2.1

-3.4+2.3-5.7+0.6-4.0

-3.8+2.8-6.6+1.0-4.8

-3.4+4.1-7.5+0.6-4.1

-4.0+4.5-8.5+1.6-5.6

15d

-10.0+4.8-14.8+0.5-10.5

-12.0+6.4-18.5+2.1-14.1

-17.3+5.5-22.8+4.2-21.5

-26.3-1.7-24.6-1.9-24.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi Consumer Healthcare India reported Q2 FY26 revenue of Rs 2,357M, up 7% YoY, with domestic sales up 12% aided by relaunch of Combiflam and Allegra suspensions. PBT rose 16% to Rs 919M and PAT grew 13% to Rs 688M. H1 FY26 revenue grew 18% to Rs 4,649M, PBT up 25%. EPS stood at Rs 29.87 for the quarter. Operating profit before working capital changes jumped from Rs 1,415M to Rs 1,789M in H1. Price Waterhouse issued a clean limited review; prior periods were reviewed by another firm, indicating an auditor change.

Likely market impact

Strong domestic-led growth, healthy cash of Rs 4,902M, but auditor change to Price Waterhouse is notable.